BioMarin seeks UK approval to begin trial of Batten disease drug

04/3/2013 | Pharmaceutical Business Review Online

BioMarin Pharmaceutical filed an application with the U.K. Medicines and Healthcare Products Regulatory Agency seeking approval to initiate a Phase I/II trial of BMN-190, an experimental drug for neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The firm expects patient enrollment for the trial to begin this year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN